Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.59 |
| ▸ | SQLE | Q14534 | 7/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3275116 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL3274058 | 0.96 | ALDH1A1 (0.61) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL5323637 | 0.96 | ALDH1A1 (0.61) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL15257167 | 0.96 | ALDH1A1 (0.61) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL15255046 | 0.96 | ALDH1A1 (0.61) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL5323634 | 0.96 | ALDH1A1 (0.61) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL15257168 | 0.83 | KDM4E (0.44) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL29059665 | 0.82 | KMT2A (0.73) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL2896117 | 0.82 | KMT2A (0.73) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL2841894 | 0.82 | KMT2A (0.73) | KMT2AKDM4EMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12064239-B2 | Device and methods for detection and monitoring of tuberculosis | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-08-20 | — | — | US | disclosed |
| US-20210282678-A1 | DEVICE AND METHODS FOR DETECTION AND MONITORING OF TUBERCULOSIS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2021-09-16 | — | — | US | disclosed |
| EP-3602044-A1 | DEVICE AND METHODS FOR DETECTION AND MONITORING OF TUBERCULOSIS | Technion Research & Development Foundation Limited (IL) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018173060-A1 | DEVICE AND METHODS FOR DETECTION AND MONITORING OF TUBERCULOSIS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2018-09-27 | — | — | WO | disclosed |
| US-20090092642-A1 | Skin and/or Hair Products, Containing Compounds With an Isoprenoid Structure | BEIERSDORF AG (DE) | 2009-04-09 | — | — | US | disclosed |
| US-20090092642-A1 | Skin and/or Hair Products, Containing Compounds With an Isoprenoid Structure | BEIERSDORF AG (DE) | 2009-04-09 | — | — | US | disclosed |
| WO-2005102252-A9 | SKIN AND/OR HAIR PRODUCTS, CONTAINING COMPOUNDS WITH AN ISOPRENOID STRUCTURE | BEIERSDORF AG (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092642-A1 | Skin and/or Hair Products, Containing Compounds With an Isoprenoid Structure | SRD5A2, SRD5A1, CUTA | KMT2A 3935/4885KDM4E 2169/4885MAPT 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.